Two polypyridyl-chelating nickel(II) and copper(II) complexes: Synthesis, structural characterization and in vitro anticancer activity in osteogenic sarcoma

Synthesis and crystal structure of a new copper(II) complex based on 5-ethyl-3-(pyridin-2-yl)-1,2,4-triazole

The title compound, bis-[μ-3-ethyl-5-(pyridin-2-yl)-1H-1,2,4-triazol-1-ido]bis[acetato-(di-methyl-formamide)-copper(II)], [Cu2(C9H9N4)2(C2H3O2)2(C3H7NO)2] or [Cu2(L Et)2(OAc)2(dmf)2], is a triazolate complex, which contains two 3-(2-pyrid-yl)-5-ethyl-triazolates (L Et)- in bidentate-bridged coordination modes. Both copper atoms are involved in the formation of a planar six-membered metallocycle Cu-[N-N]2-Cu. The inversion center of the complex is located at the mid-point of the Cu⋯Cu vector. Each CuII atom has a distorted trigonal-bipyramidal environment formed by the three nitro-gen atoms of the deprotonated bridging 3-(2-pyrid-yl)-5-ethyl-triazolate unit, oxygen atoms of the OAc- group and dmf mol-ecule. In the crystal, C-H⋯O hydrogen bonds link the mol-ecules into chains running along the c-axis direction.

A hemilabile 2-(2′-pyridyl)-imidazole based nickel(ii) complex: proton-coupled-electron-transfer, bactericidal and cytotoxicity studies

This study deals with the synthesis, structural characterization, proto-coupled-electron-transfer, bactericidal and cytotoxicity study of a hemilabile and water-soluble 2-(2′-pyridyl)-imidazole nickel(ii) complex.

Coordination compounds of biogenic metals as cytotoxic agents in cancer therapy

The review summarizes the data on the structures and methods for the synthesis of compounds with anticancer activity based on biogenic metals, which can replace platinum drugs prevailing in cytotoxic therapy. The main focus is given to the comparison of the mechanisms of the cytotoxic action of these complexes, their efficacy and prospects of their use in clinical practice. This is the first systematic review of cytotoxic zinc, iron, cobalt and copper compounds. The structure – activity relationships and the mechanisms of antitumour action are formulated for each type of metal complexes.

The bibliography includes 181 references.

Crystal structure of 2-(5-(pyridin-3-yl)-4-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)pyridine, C17H12N6

C17H12N6, monoclinic, P21/n (no. 14), a = 5.8617(14) Å, b = 15.845(4) Å, c = 15.326(4) Å, β = 92.650(5)°, V = 1422.0(6) Å3, Z = 4, R gt(F) = 0.0449, wR ref(F 2) = 0.1132, T = 296(2) K.